IS
ISCNF.US Isracann Biosciences Inc
- Market cap
- USD 1.76K
- P/E
- -
- P/B
- 0.02x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Aug 2023.
Is ISCNF.US undervalued?
Graham numberThe Graham number of Isracann Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Isracann Biosciences Inc fundamental analysis
No fundamental analysis for Isracann Biosciences Inc yet.
Isracann Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Isracann Biosciences Inc
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada.
Full company profileIsracann Biosciences Inc financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Aug 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Isracann Biosciences Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 38.6K | 186K | 322K | 1.17M | 1.32M | 0.00 | 0.00 | 0.00 | - | - |
| Gross Profit | - | -6.54K | 39.0K | 165K | 1.17M | -44.8K | -45.1K | -41.3K | -41.7K | - | - |
| Operating Income | -104K | -592K | -487K | -708K | -6.28M | -5.66M | -11.2M | -4.78M | -2.39M | - | - |
| EBITDA | -105K | -379K | -221K | -171K | -6.77M | -5.27M | -11.2M | -4.78M | -2.39M | - | - |
| Net Income | -102K | -592K | -487K | -668K | -7.47M | -9.60M | -24.2M | -25.2M | -4.69M | - | - |
| EPS | -0.04 | -0.15 | -0.09 | -0.12 | -0.33 | -0.75 | -0.26 | -0.18 | -0.03 | - | - |
| Balance Sheet | |||||||||||
| Total Assets | 170K | 1.13M | 1.05M | 1.01M | 14.6M | 16.4M | 28.3M | 4.40M | 4.09M | - | 4.04M |
| Total Liabilities | 34.4K | 80.7K | 447K | 926K | 897K | 1.04M | 1.72M | 465K | 3.80M | - | 3.91M |
| Shareholders' Equity | 136K | 1.05M | 600K | 82.0K | 13.7M | 15.3M | 26.6M | 3.94M | 294K | - | 128K |
| Cash & Short-term Investments | 166K | 13.5K | 34.6K | 224K | 8.66M | 4.18M | 3.89M | 1.96M | 214K | - | 198K |
| Total Debt | - | - | 200K | 829K | 0.00 | 0.00 | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -88.8K | -277K | -24.1K | -487K | -2.93M | -2.94M | -10.4M | -4.23M | -1.75M | - | - |
| Capital Expenditure | 0.00 | 472K | 139K | 79.7K | 5.99M | 204K | 509K | 13.7K | 0.00 | 0.00 | - |
| Free Cash Flow | -88.8K | -748K | -163K | -567K | -8.92M | -3.15M | -10.9M | -4.24M | -1.75M | - | - |
| Ratios | |||||||||||
| ROE | -75.1% | -56.4% | -81.1% | -814.8% | -54.7% | -62.6% | -91.1% | -638.7% | -1,598.1% | - | - |
| ROA | -60.0% | -52.4% | -46.5% | -66.3% | -51.3% | -58.6% | -85.6% | -571.7% | -114.7% | - | - |
| Net Profit Margin | - | -1,531.8% | -261.3% | -207.8% | -636.9% | -727.0% | - | - | - | - | - |
| Debt to Equity | - | - | 0.33x | 10.11x | 0.00x | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Isracann Biosciences Inc dividends
Isracann Biosciences Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:3 on Oct 17, 2019.
Who owns Isracann Biosciences Inc
- Insiders 0.17%
- Institutions 0.00%
- Public & others 99.83%
- Shares outstanding 176M
- Free float 176M
Isracann Biosciences Inc company profile
- Company name
- Isracann Biosciences Inc
- Ticker
- ISCNF.US
- ISIN
- CA46501D1087
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- May
- Address
- 595 Burrard Street, Vancouver, BC, Canada, V7X 1L3
- Phone
- 604-394-2551
- Website
- isracann.com
About Isracann Biosciences Inc
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. The company also develops cultivation facilities. It exports its products to Germany. The company was formerly known as Atlas Blockchain Group Inc. and changed its name to Isracann Biosciences Inc. in October 2019. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada.
Isracann Biosciences Inc management
1- Ajay Singh KailaInterim Chief Executive Officer